CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-08 | Sheena Jonathan Director | Sale 10b5-1 | −200 | $209.57 | $42K | 253,652 |
| 2026-05-08 | Sheena Jonathan Director | Sale 10b5-1 | −1,150 | $210.35 | $242K | 252,502 |
| 2026-05-05 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,887 | $206.77 | $597K | 2,379,553 |
| 2026-05-05 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,454 | $241.39 | $351K | 2,378,099 |
| 2026-05-05 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,697 | $206.77 | $351K | 2,376,402 |
| 2026-05-05 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Grant or award 10b5-1 | +2,389 | 2,378,791 | ||
| 2026-05-05 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −948 | $205.22 | $195K | 2,377,843 |
| 2026-05-04 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −722 | $206.16 | $149K | 2,382,440 |
| 2026-05-04 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −482 | $210.49 | $101K | 57,496 |
| 2026-05-01 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −291 | $206.16 | $60K | 187,220 |
| 2026-05-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −405 | $206.16 | $83K | 145,295 |
| 2026-05-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −560 | $200.95 | $113K | 144,735 |
| 2026-05-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −520 | $201.60 | $105K | 144,215 |
| 2026-05-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −505 | $203.32 | $103K | 143,710 |
| 2026-05-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −865 | $204.47 | $177K | 142,845 |
| 2026-05-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −400 | $205.31 | $82K | 142,445 |
| 2026-05-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −150 | $206.93 | $31K | 142,295 |
| 2026-05-01 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −330 | $206.16 | $68K | 222,694 |
| 2026-05-01 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −902 | $206.16 | $186K | 149,867 |
| 2026-05-01 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −313 | $206.16 | $65K | 57,978 |
Page 19 of 39 · 767 trades